Recombinant non-immunogenic staphylokinase in the treatment of patients with acute myocardial infarction

The aim of the study was to determine the efficacy of a 15 mg single bolus of new domestic thrombolytic agent Fortelysin versus Tenecteplase in patients with acute myocardial infarction. A total of 78 patients within 6 hours of ST-elevation acute myocardial infarction (STEMI) were randomized into two groups. We analyzed clinical and medical history of the patients, timelines, and the effectiveness of the reperfusion approaches. It has been found that the application of a 15 mg single bolus Fortelysin was comparable in efficacy and safety with Tenecteplase in a standard dose based on body weight.